Evidence map›Paper›PMID 23708566›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2013

Design, synthesis, molecular modeling, and biological evaluation of sulfanilamide-imines derivatives as potential anticancer agents.

Sofian S Mohamed, Abdalkarem R Tamer, Salah M Bensaber, Mousa I Jaeda, Nouri B Ermeli, Aemen Ali Allafi, Ibrahim A Mrema, Mabrouk Erhuma, Anton Hermann, Abdul M Gbaj

Open access · hybridAbstract read
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 19 citations in OpenAlex.

  1. Pharmaceutical and medicinal significance of sulfur (SEuropean journal of medicinal chemistry · 2019
    Review
  2. Article
  3. 4-{[4-(Di-methyl-amino)-benzyl-idene]amino}-benzene-sulfonamide.Acta crystallographica. Section E, Structure reports online · 2014
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Sofian S MohamedDepartment of Genetics, National Medical Research Centre, Zawia, Z16, Libya.
Abdalkarem R Tamer
Salah M Bensaber
Mousa I Jaeda
Nouri B Ermeli
Aemen Ali Allafi
Ibrahim A Mrema
Mabrouk Erhuma
Anton Hermann
Abdul M Gbaj
University of Tripoli · LYUniversity of Salzburg · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A series of sulfanilamide Schiff base derivatives (1 to 15) have been designed as potential antitubulin agents depending on the chemical structures of combretastatine A-4 and isoquinoline sulfamate (antimitotic agents under investigation). The designed compounds were synthesized by microwave chemical synthesis, their purity was confirmed by melting point and HPLC and chemical structures were determined by FT-IR, UV, and 1H and 13C-NMR spectroscopic techniques. The synthesized compounds have been docked in the colchicine binding site of β-tubulin using molecular modeling programs and the antitumor activities were screened on human breast and lung cancer cells by cell counting assay. Some tested compounds showed potent and selective activity against breast cancer (MCF-7) with IC50 range of 90 to 166 μM. With regarding broad-spectrum activity, compounds 4, 8, and 13 have shown potent antitumor activity against human breast and human lung cells with IC50 range of 96 to 140 μM. The obtained results suggest that the sulfanilamide Schiff base derivatives might potentially constitute an interesting novel class of anticancer agents, which deserve further studies.

Indexed as

Antineoplastic AgentsCell Line, TumorCell SurvivalDrug DesignHumansIminesLigandsMCF-7 CellsModels, MolecularSulfanilamidesTubulinTubulin ModulatorsAntineoplastic AgentsIminesLigandsSulfanilamidesTubulinTubulin Modulators

Identifiers

PMID23708566
PMCPMC3747319
OpenAlexW2057234182

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.